Literature DB >> 33557398

Tumor Suppressor Protein p53 and Inhibitor of Apoptosis Proteins in Colorectal Cancer-A Promising Signaling Network for Therapeutic Interventions.

Ömer Güllülü1, Stephanie Hehlgans1, Claus Rödel1,2,3,4, Emmanouil Fokas1,2,3,4, Franz Rödel1,2,3,4.   

Abstract

Despite recent advances in the treatment of colorectal cancer (CRC), patient's individual response and clinical follow-up vary considerably with tumor intrinsic factors to contribute to an enhanced malignancy and therapy resistance. Among these markers, upregulation of members of the inhibitor of apoptosis protein (IAP) family effects on tumorigenesis and radiation- and chemo-resistance by multiple pathways, covering a hampered induction of apoptosis/autophagy, regulation of cell cycle progression and DNA damage response. These mechanisms are tightly controlled by the tumor suppressor p53 and thus transcriptional and post-translational regulation of IAPs by p53 is expected to occur in malignant cells. By this, cellular IAP1/2, X-linked IAP, Survivin, BRUCE and LIVIN expression/activity, as well as their intracellular localization is controlled by p53 in a direct or indirect manner via modulating a multitude of mechanisms. These cover, among others, transcriptional repression and the signal transducer and activator of transcription (STAT)3 pathway. In addition, p53 mutations contribute to deregulated IAP expression and resistance to therapy. This review aims at highlighting the mechanistic and clinical importance of IAP regulation by p53 in CRC and describing potential therapeutic strategies based on this interrelationship.

Entities:  

Keywords:  BRUCE; LIVIN; Survivin; TP53; XIAP; cIAP1/2; colorectal carcinoma; inhibitor of apoptosis protein family

Year:  2021        PMID: 33557398      PMCID: PMC7916307          DOI: 10.3390/cancers13040624

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  185 in total

1.  A Spatial and Functional Interaction of a Heterotetramer Survivin-DNA-PKcs Complex in DNA Damage Response.

Authors:  Ömer Güllülü; Stephanie Hehlgans; Benjamin E Mayer; Ines Gößner; Chrysi Petraki; Melanie Hoffmann; Maximilian J Dombrowsky; Patrick Kunzmann; Kay Hamacher; Klaus Strebhardt; Emmanouil Fokas; Claus Rödel; Christian Münch; Franz Rödel
Journal:  Cancer Res       Date:  2021-01-06       Impact factor: 12.701

2.  Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.

Authors:  Emmanouil Fokas; Philipp Ströbel; Rainer Fietkau; Michael Ghadimi; Torsten Liersch; Gerhard G Grabenbauer; Arndt Hartmann; Marco Kaufmann; Rolf Sauer; Ullrich Graeven; Hans Hoffmanns; Hans-Rudolf Raab; Torsten Hothorn; Christian Wittekind; Claus Rödel
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506

3.  Double targeting of Survivin and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration.

Authors:  Stephanie Hehlgans; Chrysi Petraki; Sebastian Reichert; Nils Cordes; Claus Rödel; Franz Rödel
Journal:  Radiother Oncol       Date:  2013-07-03       Impact factor: 6.280

Review 4.  Survivin signaling in clinical oncology: a multifaceted dragon.

Authors:  Jagat R Kanwar; Sishir K Kamalapuram; Rupinder K Kanwar
Journal:  Med Res Rev       Date:  2012-06-11       Impact factor: 12.944

5.  Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival.

Authors:  Thilo Sprenger; Franz Rödel; Tim Beissbarth; Lena-Christin Conradi; Hilka Rothe; Kia Homayounfar; Hendrik A Wolff; B Michael Ghadimi; Müjdat Yildirim; Heinz Becker; Claus Rödel; Torsten Liersch
Journal:  Clin Cancer Res       Date:  2010-11-30       Impact factor: 12.531

Review 6.  Epigenetic regulation of DNA repair genes and implications for tumor therapy.

Authors:  Markus Christmann; Bernd Kaina
Journal:  Mutat Res Rev Mutat Res       Date:  2017-10-07       Impact factor: 5.657

7.  Survivin as a therapeutic target for radiation sensitization in lung cancer.

Authors:  Bo Lu; Yi Mu; Carolyn Cao; Fenghua Zeng; Sylke Schneider; Jiahui Tan; Jim Price; Jun Chen; Michael Freeman; Dennis E Hallahan
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

8.  Rb inactivation accelerates neoplastic growth and substitutes for recurrent amplification of cIAP1, cIAP2 and Yap1 in sporadic mammary carcinoma associated with p53 deficiency.

Authors:  L Cheng; Z Zhou; A Flesken-Nikitin; I A Toshkov; W Wang; J Camps; T Ried; A Y Nikitin
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

Review 9.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

10.  Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms.

Authors:  Osamu Kano; Kazunori Tanaka; Takuya Kanno; Yasuo Iwasaki; Joh-E Ikeda
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

View more
  3 in total

1.  The p53 Pathway Related Genes Predict the Prognosis of Colon Cancer.

Authors:  Jinggao Feng
Journal:  Int J Gen Med       Date:  2022-01-06

2.  The transcriptional activity profile of inhibitor apoptosis protein encoding genes in colon cancer patients: A STROBE-compliant study.

Authors:  Dariusz Waniczek; Marcin Nowak; Justyna Lorenc-Góra; Małgorzata Muc-Wierzgoń; Urszula Mazurek; Magda Bichalska-Lach; Zbigniew Lorenc
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

3.  The clinicopathological and prognostic significances of IGF-1R and Livin expression in patients with colorectal cancer.

Authors:  Zhenling Zhang; Yuxin Zhang; Si Lao; Jian Qiu; Ziang Pan; Xiaoying Feng
Journal:  BMC Cancer       Date:  2022-08-05       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.